LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Defibrotide for the treatment of PIMS-TS in two pediatric patients.

Photo from wikipedia

The pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) is a severe complication of Covid-19. Since impaired coagulation, thrombosis/endotheliitis are suspected pathomechanisms, we treated two patients with defibrotide… Click to show full abstract

The pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) is a severe complication of Covid-19. Since impaired coagulation, thrombosis/endotheliitis are suspected pathomechanisms, we treated two patients with defibrotide (DF), a pro-fibrinolytic, antithrombotic, anti-inflammatory oligonucleotide. Symptoms resolved during treatment. Moreover, coagulation parameters indicating hypofibrinolysis and complement activation normalized.

Keywords: defibrotide treatment; treatment; two pediatric; pims two; treatment pims; patients defibrotide

Journal Title: Journal of the Pediatric Infectious Diseases Society
Year Published: 2020

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.